[2000 Standards, Options and Recommendations for prognostic value of oncogenes and tumor suppressor genes in non small cell lung cancer].
BACKGROUND
The "Standards, Options and Recommendations" (SOR) project, started in 1993, is a collaboration between the Federation of French cancer centers (FNCLCC), the 20 French cancer centers, and specialists from French public universities, general hospitals and private clinics. The main objective is the development of clinical practice guidelines to improve the quality of health care and the outcome of cancer patients. The methodology is based on a literature review and critical appraisal by a multidisciplinary group of experts, with feedback from specialists in cancer care delivery.


OBJECTIVE
To develop clinical practice guidelines for non small cell lung cancer patients according to the definitions of the Standards, Options and Recommendations project.


METHODS
Data were identified by searching Medline , web sites, and using the personal reference lists of members of the expert groups. Once the guidelines were defined, the document was submitted for review to independent reviewers.


RESULTS
This article presents the chapter "Prognosis significance of oncogenes and tumor suppressor genes" from the full report "Standards, Options and Recommendation for non small cell lung cancer" validated in August 2000. The main recommendations are: 1) No clear clinical prognostic value of oncogenes and tumor suppressor genes (p53, bcl-2, Ki-ras, c-erbB-2, Rb, p16) in non small cell lung cancer, can be established from the available evidences (standard, level of evidence C). 2) Prospective multicenter studies should be performed to assess prognostic significance of oncogenes and tumor suppressor genes in non small cell lung cancer.
Bréchot
Jeanne-Marie
JM
FNCLCC, Standards, Options, Recommandations, 101, rue de Tolbiac, 75654 Paris Cedex 13, France.
Molina
Thierry
T
Theobald
Serge
S
Depierre
Alain
A
Lagrange
Jean-Léon
JL
Astoul
Philippe
P
Baldeyrou
Pierre
P
Bardet
Etienne
E
Bazelly
Bernard
B
Breton
Jean-Luc
JL
Douillard
Jean-Yves
JY
Grivaux
Michel
M
Jacoulet
Pascale
P
Khalil
Antoine
A
Lemarié
Etienne
E
Martinet
Yves
Y
Massard
Gilbert
G
Milleron
Bernard
B
Moro-Sibilot
Denis
D
Paesmans
Marianne
M
Pujol
Jean-Louis
JL
Quoix
Anne-Elisabeth
AE
Ranfaing
Elisabeth
E
Rivière
Alain
A
Sancho-Garnier
Hélène
H
Souquet
Pierre-Jean
PJ
Spaeth
Dominique
D
Stcebner-Delbarre
Anne
A
D002289:Carcinoma, Non-Small-Cell Lung / Q000235:genetics*; D019941:Cyclin-Dependent Kinase Inhibitor p16 / Q000235:genetics / Q000378:metabolism; D005602:France; D015972:Gene Expression Regulation, Neoplastic; D016161:Genes, Retinoblastoma; D016147:Genes, Tumor Suppressor; D018734:Genes, erbB-2; D016158:Genes, p53; D011905:Genes, ras; D006801:Humans; D008175:Lung Neoplasms / Q000235:genetics*; D009154:Mutation; D009857:Oncogenes; D011379:Prognosis; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000235:genetics / Q000378:metabolism
D019941:Cyclin-Dependent Kinase Inhibitor p16; D019253:Proto-Oncogene Proteins c-bcl-2